Leerink Partnrs Issues Optimistic Outlook for BSX Earnings

Key Points

• Leerink Partners has raised its Q1 2026 EPS estimate for Boston Scientific to $0.77, up from $0.76, maintaining a "Strong-Buy" rating on the stock.
• Boston Scientific reported Q2 earnings of $0.75 EPS, exceeding estimates and showing a 22.8% year-over-year revenue increase to $5.06 billion.
• The consensus rating for Boston Scientific stock is "Buy" with an average price target of $117.79, as noted by several analysts.

Boston Scientific Corporation (NYSE:BSX - Free Report) - Leerink Partnrs boosted their Q1 2026 EPS estimates for shares of Boston Scientific in a research note issued to investors on Tuesday, September 9th. Leerink Partnrs analyst M. Kratky now forecasts that the medical equipment provider will earn $0.77 per share for the quarter, up from their previous estimate of $0.76. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Boston Scientific's current full-year earnings is $2.85 per share. Leerink Partnrs also issued estimates for Boston Scientific's FY2027 earnings at $3.93 EPS, FY2028 earnings at $4.42 EPS and FY2029 earnings at $4.96 EPS.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the prior year, the business posted $0.62 EPS. Boston Scientific's quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS.

A number of other research firms have also issued reports on BSX. Needham & Company LLC reiterated a "buy" rating and issued a $115.00 target price on shares of Boston Scientific in a research note on Wednesday, May 28th. Robert W. Baird increased their price target on shares of Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Leerink Partners assumed coverage on shares of Boston Scientific in a report on Monday, June 16th. They issued an "outperform" rating and a $118.00 price target for the company. Royal Bank Of Canada reissued an "outperform" rating on shares of Boston Scientific in a report on Thursday, July 24th. Finally, UBS Group increased their price target on shares of Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a report on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, Boston Scientific has a consensus rating of "Buy" and an average price target of $117.79.

Boston Scientific Stock Performance

NYSE:BSX opened at $105.32 on Thursday. Boston Scientific has a 1 year low of $80.64 and a 1 year high of $109.50. The firm's fifty day simple moving average is $104.88 and its 200 day simple moving average is $102.24. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $156.06 billion, a PE ratio of 62.69, a PEG ratio of 2.60 and a beta of 0.65.

Hedge Funds Weigh In On Boston Scientific

Hedge funds and other institutional investors have recently made changes to their positions in the business. FWL Investment Management LLC bought a new position in shares of Boston Scientific during the 2nd quarter worth about $26,000. Sound Income Strategies LLC lifted its holdings in Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 120 shares during the last quarter. 1248 Management LLC bought a new position in Boston Scientific during the 1st quarter valued at about $26,000. Y.D. More Investments Ltd bought a new position in Boston Scientific during the 1st quarter valued at about $27,000. Finally, Investment Management Corp VA ADV bought a new position in Boston Scientific during the 4th quarter valued at about $25,000. 89.07% of the stock is owned by institutional investors.

Insider Buying and Selling at Boston Scientific

In other news, Director Edward J. Ludwig sold 4,000 shares of the firm's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the transaction, the director directly owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. This trade represents a 17.79% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the transaction, the executive vice president directly owned 178,342 shares of the company's stock, valued at $18,659,923.46. The trade was a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock valued at $18,397,457 over the last quarter. 0.50% of the stock is currently owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.